BACKGROUND: Skin cancer is a major public health concern, and the majority of cases are caused by solar ultraviolet radiation (UVR) exposure, which suppresses skin immunity. Omega-3 (n-3) PUFAs protect against photoimmunosuppression and skin cancer in mice, but the impact in humans is unknown. OBJECTIVES: We hypothesized that EPA-rich n-3 PUFA would abrogate photoimmunosuppression in humans. Therefore, a nutritional study was performed to assess the effect on UVR suppression of cutaneous cell-mediated immunity (CMI) reflected by nickel contact hypersensitivity (CHS). DESIGN: In a double-blind, randomized controlled study, 79 volunteers (nickel-allergic women, 22-60 y old, with phototype I or II) took 5 gn-3 PUFA-containing lipid (70% EPA plus 10% DHA) or a control lipid daily for 3 mo. After supplementation, nickel was applied to 3 skin sites preexposed on 3 consecutive days to 1.9, 3.8, or 7.6 J/cm(2) of solar-simulated radiation (SSR) and to 3 unexposed control sites. Nickel CHS responses were quantified after 72 h and the percentage of immunosuppression by SSR was calculated. Erythrocyte [red blood cell (RBC)] EPA was measured by using gas chromatography. RESULTS: SSR dose-related suppression of the nickel CHS response was observed in both groups. Photoimmunosuppression appeared less in the n-3 PUFA group than in the control group (not statistically significant [mean difference (95% CI): 6.9% (-2.1%, 15.9%)]). The difference was greatest at 3.8 J/cm(2) SSR [mean difference: 11% (95% CI: 0.5%, 21.4%)]. Postsupplementation RBC EPA was 4-fold higher in the n-3 PUFA group than in the control group (mean difference: 2.69% (95% CI: 2.23%, 3.14%), which confirmed the EPA bioavailability. CONCLUSION:Oral n-3 PUFAs appear to abrogate photoimmunosuppression in human skin, providing additional support for their chemopreventive role; verification of study findings is required. This trial was registered at clinicaltrials.gov as NCT01032343.
RCT Entities:
BACKGROUND:Skin cancer is a major public health concern, and the majority of cases are caused by solar ultraviolet radiation (UVR) exposure, which suppresses skin immunity. Omega-3 (n-3) PUFAs protect against photoimmunosuppression and skin cancer in mice, but the impact in humans is unknown. OBJECTIVES: We hypothesized that EPA-rich n-3 PUFA would abrogate photoimmunosuppression in humans. Therefore, a nutritional study was performed to assess the effect on UVR suppression of cutaneous cell-mediated immunity (CMI) reflected by nickel contact hypersensitivity (CHS). DESIGN: In a double-blind, randomized controlled study, 79 volunteers (nickel-allergic women, 22-60 y old, with phototype I or II) took 5 g n-3 PUFA-containing lipid (70% EPA plus 10% DHA) or a control lipid daily for 3 mo. After supplementation, nickel was applied to 3 skin sites preexposed on 3 consecutive days to 1.9, 3.8, or 7.6 J/cm(2) of solar-simulated radiation (SSR) and to 3 unexposed control sites. NickelCHS responses were quantified after 72 h and the percentage of immunosuppression by SSR was calculated. Erythrocyte [red blood cell (RBC)] EPA was measured by using gas chromatography. RESULTS: SSR dose-related suppression of the nickelCHS response was observed in both groups. Photoimmunosuppression appeared less in the n-3 PUFA group than in the control group (not statistically significant [mean difference (95% CI): 6.9% (-2.1%, 15.9%)]). The difference was greatest at 3.8 J/cm(2) SSR [mean difference: 11% (95% CI: 0.5%, 21.4%)]. Postsupplementation RBC EPA was 4-fold higher in the n-3 PUFA group than in the control group (mean difference: 2.69% (95% CI: 2.23%, 3.14%), which confirmed the EPA bioavailability. CONCLUSION: Oral n-3 PUFAs appear to abrogate photoimmunosuppression in human skin, providing additional support for their chemopreventive role; verification of study findings is required. This trial was registered at clinicaltrials.gov as NCT01032343.
Authors: Kyoko Miura; Mandy Way; Zainab Jiyad; Louise Marquart; Elsemieke I Plasmeijer; Scott Campbell; Nicole Isbel; Jonathan Fawcett; Lisa E Ferguson; Marcia Davis; David C Whiteman; H Peter Soyer; Peter O'Rourke; Adèle C Green Journal: Eur J Nutr Date: 2020-09-09 Impact factor: 5.614
Authors: Suzanne M Pilkington; Lesley E Rhodes; Naser M I Al-Aasswad; Karen A Massey; Anna Nicolaou Journal: Mol Nutr Food Res Date: 2013-12-05 Impact factor: 5.914
Authors: Rebecca E Fisher-Heffernan; Mamun M Or'Rashid; Ousama AlZahal; Margaret Quinton; Herman J Boermans; Brian W McBride; Timothy R H Regnault; Niel A Karrow Journal: BMC Vet Res Date: 2015-10-15 Impact factor: 2.741
Authors: Elena Talero; Sofía García-Mauriño; Javier Ávila-Román; Azahara Rodríguez-Luna; Antonio Alcaide; Virginia Motilva Journal: Mar Drugs Date: 2015-09-30 Impact factor: 5.118
Authors: Suzanne M Pilkington; Sharon A Murphy; Alexandra C Kendall; Francesco Del Carratore; Anggit L Sunarwidhi; Magdalena Kiezel-Tsugunova; Paula Urquhart; Rachel E B Watson; Rainer Breitling; Lesley E Rhodes; Anna Nicolaou Journal: FASEB J Date: 2019-09-13 Impact factor: 5.191
Authors: Anne M Minihane; Sophie Vinoy; Wendy R Russell; Athanasia Baka; Helen M Roche; Kieran M Tuohy; Jessica L Teeling; Ellen E Blaak; Michael Fenech; David Vauzour; Harry J McArdle; Bas H A Kremer; Luc Sterkman; Katerina Vafeiadou; Massimo Massi Benedetti; Christine M Williams; Philip C Calder Journal: Br J Nutr Date: 2015-07-31 Impact factor: 3.718